Point of view

Spine

Volumn 33, Issue 14, 2008, Pages 1517-

  Evans, Christopher ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BONE MORPHOGENETIC PROTEIN 2; PARVOVIRUS VECTOR;

ARTHRITIS; EXPRESSION VECTOR; GENE EXPRESSION; INTERVERTEBRAL DISK DEGENERATION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 67650714797     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e31817926ac     Document Type: Short Survey

References (6)

1. Larson JW III, Levicoff EA, Gilbertson LG, et al. Biologic modification of animal models of intervertebral disc degeneration. J Bone Joint Surg Am2006;88(Suppl 2):83-7.
2. Levicoff E, et al. Safety Assessment of intradiscal gene therapy II: effect of dosing and vector choice. Spine 2008;33:1509-16.
3. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80:148-58.
4. Evans CH, Ghivizzani SC, Robbins PD. Arthritis gene therapy's first death. Arthritis Res Ther 2008; in press.
5. Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors. Nat Protoc 2006;1:1412-28.
6. Le Maitre CL, Hoyland JA, Freemont AJ. Catabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1beta and TNFalpha expression profile. Arthritis Res Ther 2007;9:R77.